Home / Specialties / Nuclear Medicine

Nuclear Medicine

Joint RACP / RANZCR pathways (AANMS). PET, functional imaging and theranostics, a small hybrid specialty at the centre of the radioligand-therapy boom.

Diagnostics, pathology & oncology3 years AT (via RACP) or dual with radiology (longer)Competitiveness: moderateSubspecialty, entry via Basic Physician Training (Adult Medicine)
Competition snapshot: Moderate   Small posts, small pool, accessible for committed applicants (indicative)
Program length
3 years AT (via RACP) or dual with radiology (longer)
Typical entry
Post-BPT (PGY5+) or post-FRANZCR
Women (trainees)
≈ 40–50% of trainees
Consultant (public)
$300,000–460,000 package
Consultant (private)
$400,000–650,000+ (PET/theranostics private sector expanding) (indicative)
Hours & lifestyle
Office hours; effectively no emergencies
Entry routeYou enter Nuclear Medicine through Basic Physician Training (Adult Medicine): complete basic training and both divisional exams first, then compete for advanced-training posts in this specialty. This page covers what's specific to Nuclear Medicine.

Overview

Nuclear medicine physicians run PET/CT and functional imaging, and increasingly deliver therapy: radioligand treatment of prostate cancer and neuroendocrine tumours has made 'theranostics' oncology's fastest-growing modality. Entry runs via RACP advanced training (after BPT) or as a dual qualification with radiology, two doors into one small, future-facing field.

Selection and points

How selection works

ComponentWhat it involves
AT/department applicationSmall number of accredited departments; CV/referees/interview locally.
The unofficial view
  • A PET-department research project makes you known to most of the tiny national community at once; physics comfort helps.

Competition & demographics

Competitiveness

  • Small intake, small applicant pool; radiology-dual routes are the more contested door.

Who's in the program

  • Balanced cohort; metro-concentrated departments.

How to improve your chances at each stage

StageResident (PGY2–3)
  • Via BPT: oncology/endocrine terms + a PET/theranostics project; via radiology: plan the dual early.
StageRegistrar years & applications
  • Position at a theranostics-active centre; the therapeutic arm is where the field's future jobs are.
StageIf you don't get on (or change your mind)
  • Adjacent: radiology, radiation oncology, medical oncology, endocrinology.

See also the general strategy guide: universal CV, referee and interview advice that applies across specialties.

Job market & workforce outlook

Outlook: Theranostics (Lu-PSMA and successors) is transforming the field from diagnostic-only to therapeutic, demand rising ahead of workforce
  • Theranostics expansion outpacing trained workforce; private PET growing; departments small so openings lumpy; flexibility is wise.

Income

  • $400,000–650,000 indicative in private-inclusive practice.

Pre-tax, indicative, and highly variable with hours, setting and billing model. ATO figures are averages of taxable income by reported occupation.

Subspecialties & special interests

AreaNotes
TheranosticsRadioligand therapy, the boom
PET/CT + hybrid imagingCore diagnostics

Community: questions and perspectives

CommunityAsk questions and share real-world experience below. Sign in with your email (button top right) to post. Your training stage and specialty interest appear beside your name so readers know the perspective, and the best posts are folded into the page at each annual review.

❓ Questions & answers

Loading…

🩺 Experiences, corrections & perspectives

If you've trained in nuclear medicine, or tried to, share what the page can't capture: what it's really like, what's changed, what you wish you'd known.

Loading…

Last reviewed July 2026. Details marked “verified” were checked against official/current sources at review; unmarked figures are indicative estimates from training data, college publications and community knowledge. Selection regulations change annually, always read the current-year official documents before acting.